Showing results (151-160 of 190) with videos related to

Sort By:
Pageof 19
Breast Cancer Research : BCR|July 10, 2010
Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapyJohn M S Bartlett, Jeremy Thomas, Douglas T Ross, et al.
The Lancet. Oncology|January 19, 2010
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)John M S Bartlett, Alison F Munro, Janet A Dunn, et al.
Health Technology Assessment (Winchester, England)|February 12, 2016
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancerRobert C Stein, Janet A Dunn, John M S Bartlett, et al.
Journal of the National Cancer Institute|August 12, 2025
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patientsMatteo Lambertini, Deirdre Allegranza, Ruediger P Laubender, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2012
Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012Matthias Preusser, Frank Winkler, Laurence Collette, et al.
The Oncologist|May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBCNaoto T Ueno, Francesco Cottone, Kyle Dunton, et al.
The Lancet. Oncology|May 17, 2011
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trialHervé Bonnefoi, Martine Piccart, Jan Bogaerts, et al.
BMJ Open|November 29, 2023
Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocolMark A Hull, Pei Loo Ow, Sharon Ruddock, et al.
Health Technology Assessment (Winchester, England)|May 9, 2026
Comparing the effectiveness, cost-effectiveness and implementation of low-dose oral modified release morphine in people with chronic breathlessness: a synopsis of a RCT and process evaluationMiriam J Johnson, Bronwen Williams, Catriona Keerie, et al.
Breast Cancer Research and Treatment|March 1, 2023
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II studyAilsa J Oswald, Stefan N Symeonides, Duncan Wheatley, et al.
Pageof 19